Conmed (CNMD) Tops Q1 EPS by 9c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
CONMED (CNMD) PT Raised to $73 at Needham & Company
April 26, 2018 6:54 AM EDTNeedham & Company raised its price target on CONMED (NASDAQ: CNMD) to $73.00 (from $71.00) while maintaining a Buy rating.
Analyst Mike Matson commented, "CNMD's 1Q18 revenue and EPS beat consensus and management raised its 2018 revenue and EPS guidance. Revenue growth slowed somewhat to 6.8% CC... More
